Deutsche Bank retained AstraZeneca PLC (LON:AZN) to Buy in a report released earlier today.
- Updated: September 27, 2016
Deutsche Bank has retained AstraZeneca PLC (LON:AZN) to Buy in a report released on Wednesday September 28, 2016.
Having a price of 5,075.00GBX, AstraZeneca PLC (LON:AZN) traded -0.80% lower on the day. With the last stock price close up 15.31% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. AstraZeneca PLC has recorded a 50-day average of 5,023.51GBX and a two hundred day average of 4,386.43GBX. Volume of trade was down over the average, with 2,143,824 shares of AZN changing hands under the typical 2,722,760
Recent Performance Chart
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a PE ratio of 28.90 AstraZeneca PLC’s market capitalization is presently 0 GBX.
A total of 29 analysts have released a report on the company. Four equity analysts rating the company a strong buy, 14 firms rating the stock a buy, thirteen analysts rating the company a hold, two equity analysts rating the company a underperform, and finally one firm rating the stock a sell with a consensus target price of 61.96GBX.
About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.